Brochure Design 2020 04 15 V2

Total Page:16

File Type:pdf, Size:1020Kb

Brochure Design 2020 04 15 V2 D I S C O V E R Rapid Assays Rapid Reliable Expedient T E S T, D I A G N O S E & T R E A T RAPI DAS SAYS ImmunoScience India Pvt. Ltd. Gat No. 41, Village Kusgaon, Shivapur-Velhe Road, Taluka: Bhor, Pune 412205 Maharashtra, India An ISO 9001:2015 and ISO 13485:2016 Company [email protected] OUR NEWEST ADDITION ImmunoQuick Covid-19 IgM/IgG Rapid test for the detection of IgM and IgG antibodies in serum or plasma. Tested by National Institute of Virology, Pune. ImmunoQuick One StepPregnancy Pregnancy Test Device / Dipstick Intended Use : ImmunoQuick Pregnancy, est Pregnancy evice immunoassay for the rapid and visual determination of hCG (human Chorionic D O p Pregnancy T Pregnancy p n e te S te p S ne P D O r e e Pregnancy vic g Gonadotropin) hormone in human urine specimen to aid in the early detection of n e a n c y T e s t pregnancy. Two Formats ISO 9001 : 2015 ISO 13485 : 2016 } Certified Company est 25 One Step Procedure - T cy Pregnancy regnan Dipstick O n Fast - e P tep S - Device (Cassette) and Dipstick (Strip) te p S ne P D O ip r e Pregnancy s g tic n a k n c Duration - Result as early as 30 Seconds y T e One step pregnancy test is a self testing st Clear Results - 5 minutes Easy to use, ISO 9001 : 2015 } Certified Company ISO 13485 : 2016 Early detection - 25 High Sensitivity - Easy to interpret with clear test andSample dark control dropper bands provided with device format. High Specificity - levels Detection of hCG after first day of missed period ImmunoQuick No hook effect - Detects 10m IU/ml hCG in urine sample Storage - No cross reactivity with other hormones like LH, FSH, TSH at normal Malaria Pf Rapid Malaria Good stability – Room temperatureNo decrease storage in test or between line intensity 4°C to at 30°C. high hCG concentration Pf (HRP 2) Pack size – DeviceAntigen / Dipstick Test ConvenientStable and foraffordable two years 1/10/25 tests per pack Intended Use : , 2) immunoassay for the detection of P.falciparumspecific histidine rich protein-2 (Pf. HRP- Malaria Pf Malaria est Device est 2) antigen from human whole blood samples. R a T Antigen p A id n (HRP Pf Malaria Rapid M tig a e la n Malaria Pf T ria Two formats - e P s t D f (H ImmunoQuick Malaria Pf, e v R ic P e 2 ) Two step procedure - Test duration - ISO 9001 : 2015 } Certified Company ISO 13485 : 2016 Clear results - Device (Cassette) and Dipstick (Strip) 25 High sensitivity – 2) P R Malaria Pf Malaria parasite density as low as 5020 parasites/ minutes l from Pf positive samples. est Dipstick est Easy to use. Assay Buffer bottle and sample applicator/loop provided. alaria Pf(H alaria R a Fast background clearing easy to interpret with clear test and control bands A p id T Antigen High specificity - n tig M apid M R e a n la A Malaria Pf T ria e s P t D f (H negative malaria samples and microscopy positive P. vivax positive samples No cross Rapid in vitro, qualitative lateral flow ip s R tic P k 2 ) 100% positive results in comparison to Microscopy. Detects samples with reactivity with HAMA and RF/RA positive samples. Storage - ISO 9001 : 2015 ISO 13485 : 2016 } Certified Company 100% specific to Pf specific HRP 2. No cross reactivity with microscopy Good stability – 25 Pack size – Room temperature storage or between 4°C to 40°C. m ConvenientStable and for affordable two years 1/10/25 tests per pack ImmunoQuick Malaria Pf/Pv Pf(HRP 2) / Pv (pLDH) Rapid Malaria Antigen Test - Device Intended Use : immunoassay for the detection of P.falciparumspecific histidine rich protein-2 (Pf. HRP- 2) and P. vivax specific plasmodium Lactate DeHydrogenase (pLDH) from human whole blood samples. The test may also be used for the differentiation between P. Malaria Pf/Pv Malaria falciparum and P.vivax infection.ImmunoQuick Malaria Pf/Pv, Rapid Malaria Pf (HR Antigen Test Device Test Antigen Format - Malaria Pf/Pv Antigen T Rapid Malaria Pf (HRP 2) / Pv (pLDH) Pv / 2) (HRP Pf Malaria Rapid Two step procedure - est Device P 2) / Pv (pLDH) loop provided Device (Cassette) Test duration - ISO 9001 : 2015 } Certified Company ISO 13485 : 2016 Clear results - 25 bands. Separate Pf test line and Pv test line for detection of Pf and Pv infection. Easy to use. Assay Buffer bottle and disposable sample applicator/ High sensitivity – 20 minutes A rapid, in vitro, qualitative, lateral flow parasite density as low asFast 50 parasites/background l for clearing Pf positive easy toand interpret Pv positive with samples. clear test and dark control High specificity - with microscopy negative malaria samples. No cross reactivity with HAMA and RF/RA ImmunoQuick positive samples 100% positive results in comparison to Microscopy. Detects samples with Malaria Pf/PAN Storage - Pf (HRP2) / PAN (pLDH) Good stability – 100% specific to Pf specific HRP2 and Pv specific pLDH. No cross reactivity Rapid Malaria Antigen Test - Device Pack size – Room temperature storage or between 4°C to 40°C. Intended Use : m flow immunoassayConvenient for theStable detectionand affordablefor two of years P.falciparum 1/10/25 tests specific per pack histidine rich protein-2 (Pf. HRP-2) and PAN malaria specific plasmodium Lactate DeHydrogenase (pLDH) from human whole blood samples. The test may also be used for the differentiation of P. falciparum and other malarial species (Pv, Pm, Po) and for the follow up of anti-malarial therapyImmunoQuick in whole bloodMalaria samples Pf/PAN, Malaria Pf/PAN Malaria Format - Antigen Test Device Test Antigen Rapid M Malaria Pf/P alaria Pf (HRP Rapid Malaria Pf (HRP 2) / PAN (pLDH) PAN / 2) (HRP Pf Malaria Rapid Two step procedure - Antigen T est Device loop provided. AN 2) / P Device (Cassette) AN (pLDH) Test duration - Clear results - bands. Separate Pf test line for detection of Pf and PAN test line for detection of Pf and ISO 9001 : 2015 ISO 13485 : 2016 } Certified Company non-falciparum malarial ( P. vivax, malariae, ovale ) infection. 25 High sensitivity – 20 minutes Easy to use. Assay Buffer bottle and disposable sample applicator/ Fast background clearing , easy to interpret with clear test and dark control ImmunoQuick parasite density as low as 50 parasites/ l for Pf positive and Pv positive samples. A rapid, in vitro, qualitative, lateral High specificity - Dengue NS1 microscopy negative malaria samples. No cross reactivity with HAMA and RF/RA positive Dengue NS1 Antigen samples Storage - 100% positive results in comparison to Microscopy. Detects samples with Rapid Good stability – Test - Device Pack size – 100% specific to Pf specific HRP 2 and PAN pLDH. No cross reactivity with Room temperature storage or between 4°C to 40°C. Intended Use : , Convenient and affordable 1/10/25 tests per pack immunoassay for the detectionStable of for Dengue two years Specific non-structural protein 1 (NS1) in Dengue NS 1 NS Dengue m Device human serum, plasma or whole blood. Rapid Dengue NS 1 Rapid Dengue NS 1 Antigen Test 1 Antigen NS Dengue Rapid Dengue NS 1 Format - Device ImmunoQuick Dengue NS1, Antigen T One step procedure - est Test duration - Device (Cassette) ISO 9001 : 2015 } Certified Company ISO 13485 : 2016 Clear results - 25 High sensitivity – High specificity - 15 minutes Easy to use. Sample dropper provided. HAMA and RF/RA positive Fastsamples clearing easy, to interpret with clear test and dark control bands Rapid in vitro, qualitative lateral flow Storage - 100% positive results with Dengue NS1 positive samples. Good stability – 100% negative results with negative samples. No cross reactivity with Pack size – Room temperature storage or between 4°C to 30°C. ConvenientStable and foraffordable two years 1/10/25 tests per pack Intended Use : ImmunoQuick Dengue IgG/IgM, A Rapid, in vitro, qualitative lateral ImmunoQuick flow immunoassay for the detection of Dengue specific IgG/IgM antibodies in human Dengue IgG/IgM serum/plasma. Rapid Dengue IgG/IgM Format - Device (Cassette) Test - Device Two step procedure - Easy to use. Sample applicator/dropper, Assay buffer bottle provided. Test duration - 15 minutes G M /Ig ice /Ig M G Ig t Dev t e Ig e e gu Tes gu n en e D D Clear results - Fast background clearing, easy to interpret with clear test and dark control id ap R bands Certified Company RapidDengue Dengue IgG/IgM IgG/IgM } Test Device ISO 9001 : 2015 ISO 13485 : 2016 High sensitivity – 100% positive results with Dengue IgG and IgM positive samples. 25 High specificity - 100% negative results with negative samples. Storage - Room temperature storage or between 4°C to 30°C. Good stability – Stable for Two Years Pack size – Convenient and affordable 1/10/25 tests per pack Intended Use : ImmunoQuick Dengue Combo, Rapid, in vitro, qualitative, lateral ImmunoQuick flow immunnoassay for the detection of Dengue NS1 Antigen & Dengue specific Dengue Combo IgM/IgG antibodies in human serum/plasma. Rapid Dengue Combo Format - Two separate devices for Dengue NS1 Antigen & Dengue IgG/IgM Antibody. (Ag+Ab) Test Device Procedure - Dengue NS1 - Easy to use. Sample Dropper provided. Dengue IgM/IgG - Easy to use Sample applicator/dropper, Assay buffer bottle provided. Test duration - 15 minutes o b m o est Device est C Clear results - Fast background clearing, easy to interpret with clear test and dark control e u g en D (Ag+Ab) T (Ag+Ab) Rapid Dengue Combo Dengue Rapid bands Certified Company High sensitivity – 100% positive results with Dengue NS1 & IgG and IgM positive samples. RapidDengue Dengue Combo Combo } (Ag+Ab) T ISO 9001 : 2015 est Device ISO 13485 : 2016 25 High specificity - 100% negative results with negative samples.
Recommended publications
  • Dengue–COVID-19 Coinfection: the First Reported Case in the Philippines
    Case Report/Case Series Dengue–COVID-19 coinfection: the first reported case in the Philippines Angyap Saipen,a Bernard Demot,a Lowella De Leona Correspondence to Angyap Lyn Saipen (email: [email protected]) The rainy season in the Philippines is from June to October; this is when the number of dengue cases typically increases. In 2020 during this time, the world was facing the threat of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection. Coronavirus disease 2019 (COVID-19) and dengue viral infections have similar presentations and laboratory findings, including fever and thrombocytopenia, and there have been reports of coinfection with SARS-CoV-2 and arthropod-borne virus. Here, we report a case of SARS-CoV-2–dengue virus coinfection in the Philippines in a female aged 62 years, whose early symptom was fever and who was positive for SARS-CoV-2 and positive for dengue. Early recognition of such coinfection is important so that proper measures can be taken in the management of the patient. engue fever is a mosquito-borne viral infection fever (highest recorded at 39.5 °C), with associated found mostly in tropical climates, including headache (frontoparietal in location, rated 5/10 and Dthe Philippines. The clinical manifestations of bandlike in character) and retro-orbital pain, general- dengue may include high-grade fever, headache, retro- ized body ache, myalgia and arthralgia. There was no orbital pain, muscle and joint pains, and rashes. In associated nausea, vomiting or blurring of vision. The 2019, the Philippines had one of the highest numbers patient had pain over the ankle joints, with no associ- of reported dengue cases among countries in Asia ated warmth or limitation of movement, and no rashes, and South-East Asia.1 According to the World Health cough or dyspnoea.
    [Show full text]
  • VDL Annual Report
    2010 Annual Report Table of Contents ISU VDL Mission Statement .......................................................................................................................... 3 VDPAM Organizational Chart ....................................................................................................................... 4 VDPAM External Advisory Board .................................................................................................................. 5 VDL Faculty List ............................................................................................................................................ 6 VDL Staff List ................................................................................................................................................ 7 New Tests Introduced ................................................................................................................................... 9 2010 Statistical Data ................................................................................................................................... 10 Accessions .............................................................................................................................................. 10 Tests ....................................................................................................................................................... 11 Submission Trends ................................................................................................................................
    [Show full text]
  • 69292/2020/Estt-Ne Hr 5
    5 69292/2020/ESTT-NE_HR Index Sr. No. Particulars Page No. 1 General Billing Rules 2--11 2 Packages Detail 12--23 3 Room Rent 24--25 4 Consultation Charges. 26--32 5 CTVS PACKAGE ROCEDURES 33--35 6 CTVS PEDIATRIC 36--37 7 CATH ADULT PROCEDURES 38--39 8 EP STUDY PACKAGE PROCEDURES 40--41 9 PEDIATRIC CATH PROCEDURES 42--43 10 UROLOGY PROCEDURES 44--46 11 NEPHROLOGY PROCEDURES 47-52 12 VASCULAR SURGERY 53--54 13 GENERAL SURGERY PROCEDURE 55--62 14 NUEROLOGY PROCEDURES 63--67 15 UROLOGY 68--71 16 DENTAL PROCEDURES 72--78 17 DERMATALOGY PROCEDURES 79--82 18 ENT PROCEDURES 83--87 19 NEPHROLOGY 88--89 20 GYNECOLOGY PROCEDURES 90--93 21 LABORATORY TEST CHARGES 94-120 22 ONCOLOGY PROCEDURES 121-126 23 OPTHALMOLOGY PROCEDURES 127-130 24 PULMONOLOGY PROCEDURES 131-134 25 PAIN CLINIC CHARGES 135-136 26 PLASTIC SURGERY 137-141 27 PHYSIOTHERAPY CHARGES 142-144 28 MISC. & OTHER SERVICES 145-148 29 CARDIAC DIAGNOSTIC CHARGES 149-151 30 CT PROCEDURES 152-155 31 MRI PROCEDURES 156-162 32 X RAY PROCEDURES 163-166 33 ULTRASOUND PROCEDURES 167-169 34 DIAGNOSTIC NEUROLOGY 170-172 35 DIANG-HIS 173-174 36 BLOOD BANK 175-176 37 GASTROENTEROLOGY PACKAGES 177-178 38 GASTROENTEROLOGY 179-184 39 TRANSPLANT CHARGES 185-186 0 6 69292/2020/ESTT-NE_HR 40 ORTHOPAEDIC PACKAGES 187-189 41 ORTHOPAEDICS PROCEDURES 190-199 42 MAXILLOFACIAL SURGERY 200-206 43 ONCO SURGERY 207-209 44 INTERVENTIONAL RADIOLOGY & CARDIOLOGY 210-211 45 ANESTHESIA PROCEDURES 212-214 46 PSYCHOLOGY 215-216 1 7 69292/2020/ESTT-NE_HR GENERAL BILLING RULES & GUIDELINES 2 8 69292/2020/ESTT-NE_HR Registration and Admission Charges a) Onetime Registration charges of INR.100/- shall be charged to all new patients coming to Hospital for the first time.
    [Show full text]
  • Severe Dengue Due to Secondary Hemophagocytic Lymphohistiocytosis
    IDCases 8 (2017) 50–53 Contents lists available at ScienceDirect IDCases journal homepage: www.elsevier.com/locate/idcr Case report Severe dengue due to secondary hemophagocytic lymphohistiocytosis: A case study Ujjwayini Ray*, Soma Dutta, Susovan Mondal, Syamasis Bandyopadhyay Apollo Gleneagles Hospitals, 58, Canal Circular Road, Kolkata 70054, West Bengal, India A R T I C L E I N F O A B S T R A C T Article history: Received 17 March 2017 Dengue, transmitted by the mosquito Aedes aegypti affects millions of people worldwide every year. Received in revised form 25 March 2017 Dengue induced hemophagocytic lymphohistiocytosis (HLH) is a serious condition and may prove fatal if Accepted 25 March 2017 not detected early and treated appropriately. Diagnosis of HLH is challenging and usually missed as Available online xxx clinical and laboratory findings are nonspecific. Moreover, the pathophysiology of the systemic inflammatory response syndrome and/or sepsis is remarkably similar to HLH. Secondary HLH following Keywords: infection by the dengue virus is now being increasingly recognized as a cause of severe form of the Bicytopenia disease. We report a case of dengue associated HLH in an otherwise healthy person who deteriorated Dengue during the course of hospitalization. A disproportionately high ferritin level and persistent bicytopenia Hemophagocytic lymphohistiocytosis prompted investigations for HLH. Diagnosis of dengue fever with virus-associated hemophagocytic (HLH) Infection syndrome was established according to the diagnostic criteria laid down by the Histiocyte Society. We discuss the diagnosis and management of this complex case and try to generate awareness about dengue Intravenous immunoglobulin G induced HLH as one of the possible causes for severe manifestations of this infection © 2017 The Authors.
    [Show full text]
  • Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays
    diagnostics Article Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays Li Kiang Tan 1, Wing Yan Wong 1, Hui Ting Yang 1, Roland G. Huber 2 , Peter J. Bond 2,3, Lee Ching Ng 1,4, Sebastian Maurer-Stroh 2,3 and Hapuarachchige Chanditha Hapuarachchi 1,* 1 Environmental Health Institute, National Environment Agency, Singapore 38667, Singapore; [email protected] (L.K.T.); [email protected] (W.Y.W.); [email protected] (H.T.Y.); [email protected] (L.C.N.) 2 Bioinformatics Institute, Agency for Science, Technology and Research, Singapore 138671, Singapore; [email protected] (R.G.H.); [email protected] (P.J.B.); [email protected] (S.M.-S.) 3 Department of Biological Sciences, National University of Singapore, Singapore 117558, Singapore 4 School of Biological Sciences, Nanyang Technological University, Singapore 639798, Singapore * Correspondence: [email protected]; Tel.: +65-65115335; Fax: +65-65115339 Received: 7 November 2019; Accepted: 23 December 2019; Published: 24 December 2019 Abstract: Dengue virus (DENV) and Zika virus (ZIKV) are flaviviruses of public health relevance. Both viruses circulate in the same endemic settings and acute infections generally manifest similar symptoms. This highlights the importance of accurate diagnosis for clinical management and outbreak control. One of the commonly used acute diagnostic markers for flaviviruses is nonstructural protein 1 (NS1). However, false positives due to antigenic cross-reactivity have been reported between DENV and ZIKV infections when using DENV NS1 antigen (NS1 Ag) detection assays in acute cases. Therefore, we investigated the lowest detectable virus titres and cross-reactivity of three commercial dengue NS1 Ag rapid assays and two ELISAs for different flaviviruses.
    [Show full text]
  • Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at Least After 5 Days of Infection
    Research Article Anatomy Physiol Biochem Int J Volume 4 Issue 2- February 2018 Copyright © All rights are reserved by Sudipta Poddar DOI: 10.19080/APBIJ.2017.04.555632 Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at least after 5 Days of Infection Sudipta Poddar* and Amiya Kumar Hati Department of Medical Physiology, Lincoln University College, Malaysia Submission: January 01, 2017; Published: February 09, 2018 *Corresponding author: Sudipta Poddar, Department of Medical Physiology, Lincoln University College, 47301, Petaling Jaya, Malaysia; Email: Abstract Objectives: The objective of this paper is to detect the NS1 antigen beyond 5 days of infection in serologically confirmed dengue cases in whom both NS1 antigen and IgG and IgM antibodies were assessed. Methods: Out of a total of 1037 suspected persons 257 i.e. 24.78% were dengue reactive in 2013 and 2014. Dengue cases were diagnosed in the laboratory from suspected patients by dengue specific IgG, IgM antibodies and NS1 antigen. NS1 antigen and IgG antibodies were monitored in 220 (194+26) suspected dengue cases where interpretation was possible to detect NS1 beyond 5 days of infection. This study of detection of NS1 antigen in serologically confirmed dengue cases at least after 5 days of infection. Results: Among this 220 cases 86 (80+6) were confirmed dengue cases. Out of these 86 cases NS1 antigen was found beyond 5 days of infection in 15 i.e. 17.44%. Conclusion: It would be reasonable to believe that many such cases would be found in the category I where only NS1 was tested. Hence for getting the information on NS1 antigen beyond 5 days all three serological tests (NS1 antigen, IgG and IgM antibodies) should be performed.
    [Show full text]
  • The Point-Of-Care Diagnostic Landscape for Sexually Transmitted Infections (Stis)
    The Point-of-Care Diagnostic Landscape for Sexually Transmitted Infections (STIs) Maurine M. Murtagh The Murtagh Group, LLC 2019 1 Introduction Sexually transmitted infections (STIs) continue to be a significant global public health issue, with an estimated 378 million people becoming ill in 2016 with one of 4 STIs: syphilis, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) (1) . In addition, more than 291 million women have a human papillomavirus (HPV) infection, which is a necessary cause of high grade cervical intraepithelial neoplasia (grade 2 or higher [CIN2+]) (1). This report considers the available and pipeline diagnostics for curable STIs, namely syphilis, CT, NG, TV, and HPV. With some exceptions, the existing diagnostics for these STIs are laboratory-based platforms, which typically require strong infrastructure and well-trained laboratory technicians. In addition, test turnaround time (TAT) is often long, requiring patients to return for test results on a subsequent clinic visit. This, in turn, leads to significant loss to follow-up. Therefore, while these laboratory-based diagnostics are effective, they may not always be suitable for use in resource-limited settings where diagnostic access and delivery are difficult. There are now a variety of tests available for use at or near the point of patient care (POC) for STIs (2). These include a wide range of rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and syphilis, among others, with which it is possible to detect infection using fingerprick blood, or in some cases, oral fluid.1 In addition, other types of POC tests, including simple molecular tests for use in primary healthcare settings, have also become available recently.
    [Show full text]
  • The Point-Of-Care Diagnostic Landscape for Sexually Transmitted Infections (Stis)
    The Point-of-Care Diagnostic Landscape for Sexually Transmitted Infections (STIs) Maurine M. Murtagh The Murtagh Group, LLC 31 May 2018 1 Sexually transmitted infections (STIs) continue to be a significant global public health issue, with an estimated 357 million people becoming ill each year with one of 4 STIs: syphilis, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) (1). In addition, more than 290 million women have a human papillomavirus (HPV), which infection is a necessary cause of high grade cervical intraepithelial neoplasia (grade 2 or higher [CIN2+]) (1). This report considers the available and pipeline diagnostics for curable STIs, namely syphilis, CT, NG, TV, and HPV. With some exceptions, the existing diagnostics for these STIs are laboratory-based platforms, which typically require strong laboratory infrastructure and well-trained laboratory technicians. In addition, test turnaround time is often long, requiring patients to return for test results on a subsequent clinic visit. This, in turn, leads to significant loss to follow-up. Therefore, while these laboratory-based diagnostics are effective, they may not always be suitable for use in resource-limited settings where diagnostic access and delivery are difficult. There are now a variety of tests available for use at or near the point of patient care (POC) for STIs (2). These include a wide range of rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV), hepatitis C virus and syphilis, among others, with which it is possible to detect infection using fingerprick blood, or in some cases, oral fluid.1 In addition, other types of POC tests, including simple molecular tests for use in primary healthcare settings, have also become available recently.
    [Show full text]
  • Design and Development of Small Molecule Based Biosensors for Detection of Pathogens
    Georgia State University ScholarWorks @ Georgia State University Chemistry Dissertations Department of Chemistry Fall 12-3-2018 Design and development of small molecule based biosensors for detection of pathogens Amrita Das Amrita Das Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss Recommended Citation Das, Amrita, "Design and development of small molecule based biosensors for detection of pathogens." Dissertation, Georgia State University, 2018. https://scholarworks.gsu.edu/chemistry_diss/159 This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. i DESIGN AND DEVELOPMENT OF SMALL MOLECULE BASED BIOSENSORS FOR DETECTION OF PATHOGENS by AMRITA DAS Under the Direction of Suri S Iyer. Ph.D. i ii ABSTRACT Glycans are present on the cell surface of mammalian cells. In Dr. Iyer’s laboratories, we aim to understand the interactions of cell surface glycans with toxins and pathogens at a molecular level and use that information to develop a point of care diagnostics. This thesis primarily focuses on the development of new technologies that could potentially be further developed towards the point of care diagnostics. Chapter 1, the introduction chapter focuses on the biosensors, different recognition molecules, various reporters, techniques, testing parameters used in biosensors and point of care testing (POCT). In chapter 2, the focus is on the development of a novel electrochemical assay that uses repurposed glucose meters for the detection of different analytes.
    [Show full text]
  • Dengue–COVID-19 Coinfection
    COVID-19: Case Report/SeriesArticle type Dengue–COVID-19 coinfection: the first reported case in the Philippines Angyap Saipen,a Bernard Demot,a Lowella De Leona Correspondence to Angyap Lyn Saipen (email: [email protected]) The rainy season in the Philippines is from June to October; this is when the number of dengue cases typically increases. In 2020 during this time, the world was facing the threat of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection. Coronavirus disease 2019 (COVID-19) and dengue viral infections have similar presentations and laboratory findings, including fever and thrombocytopenia, and there have been reports of coinfection with SARS-CoV-2 and arthropod-borne virus. Here, we report a case of SARS-CoV-2–dengue virus coinfection in the Philippines in a female aged 62 years, whose early symptom was fever and who was positive for SARS-CoV-2 and positive for dengue. Early recognition of such coinfection is important so that proper measures can be taken in the management of the patient. engue fever is a mosquito-borne viral infection fever (highest recorded at 39.5 °C), with associated found mostly in tropical climates, including headache (frontoparietal in location, rated 5/10 and Dthe Philippines. The clinical manifestations of bandlike in character) and retro-orbital pain, general- dengue may include high-grade fever, headache, retro- ized body ache, myalgia and arthralgia. There was no orbital pain, muscle and joint pains, and rashes. In associated nausea, vomiting or blurring of vision. The 2019, the Philippines had one of the highest numbers patient had pain over the ankle joints, with no associ- of reported dengue cases among countries in Asia ated warmth or limitation of movement, and no rashes, and South-East Asia.1 According to the World Health cough or dyspnoea.
    [Show full text]
  • Sd Product Catalog
    SD PRODUCT CATALOG Ordering When you place an order, please inform us of full description, product catalog number, unit size, quantity required including any special instructions with the correct billing and shipping address. Please note that individual products may have different specifications in various markets. Also, some products may not be available in all markets worldwide, only in selected markets. Standard Diagnostics, Inc. 65, Borahagal-ro, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea Tel No. : +82-31-899-2800 Fax No. : +82-31-899-2840 E-Mail : [email protected] Cancellation Any order cancellation should be informed to us within 2 days after placing purchase order. Special custom or large volume orders can not be cancelled at our sole discretion. Pricing Prices will be quoted upon request in US Dollars and are subject to change without prior notice. Quantity discounts are available for bulk. Payment Terms All orders are prepaid unless prior credit arrangements have been made with our Finance Department. All orders are F.O.B. from our factory. Freight charges and insurance charges are the responsibility of the customer. Prices are subject to change without prior notice. Shipping Shipments are made on FCA basis unless otherwise specified. The cost of courier service and special handling if requested shall be the customer’s responsibility. Please specify your shipping requirements when placing your order. Returned Goods Policy No returns shall be accepted without prior approval from SD in the form of an assigned Return Goods Authorization (RGA) Number. To return unused products in error sent to you, please contact us for a RGA Number and further details.
    [Show full text]
  • Evaluation of NS1 Antigen Detection As Point of Care Test Against Other Dengue Markers
    Int.J.Curr.Microbiol.App.Sci (2015) 4(11): 289-294 International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 289-294 http://www.ijcmas.com Original Research Article Evaluation of NS1 Antigen Detection as Point of Care Test against Other Dengue Markers C.S. VinodKumar1*, B.S. Prasad2, Satish Patil1, N.K. Kalappanavar2, S.G. Jayaraj3, K.G. Basavarajappa1, Rithesh Kumar1 and S. Chethan Kumar1 1Department of Microbiology, S. S. Institute of Medical Sciences & Research Centre, NH-4, Bypass Road, Davangere, Karnataka, India 2Department of Pediatrics, S. S. Institute of Medical Sciences & Research Centre, NH-4, Bypass Road, Davangere, Karnataka, India 3Department of Medicine, S. S. Institute of Medical Sciences & Research Centre, NH-4, Bypass Road, Davangere, Karnataka, India *Corresponding author ABSTRACT Early and accurate diagnosis is need for hour in cases of dengue virus infection. The present study was conducted to evaluate the usefulness of the dengue NS1 antigen with other dengue biomarkers. A total of 306 samples collected from the fever of unknown origin (FUO) during the period July 2014 to March 2015 were K eywo rd s tested for dengue fever parameters such as dengue NS1 antigen, dengue antibody tests (IgM, IgG) by rapid immunochromatography, RT-PCR for the presence of Dengue fever, dengue virus RNA and CBC. Out of 306, 47(15%) were positive for dengue virus NS1 antigen, infection by RT PCR, among them 89.4% were infected with single DENV RT- PCR, serotype and 10.6% had concurrent infection. 45 samples were positive for NS1 Dengue antigen test, of which 43 were positive in samples which were positive for RT PCR antibodies and 2 samples were positive in RT PCR negative samples.
    [Show full text]